Ravi; National Tumor Institute SPORE (5P50CA096784-05) to J

Ravi; National Tumor Institute SPORE (5P50CA096784-05) to J.A. of TGF- compared with untreated tumor-bearing mice. Although treatment with cetuximab only forced the natural selection of TGF-overexpressing tumor cells in nonregressing tumors, combinatorial treatment with cetuximab and a TGF-blocking antibody prevented the MCH-1 antagonist 1 emergence of such resistant tumor cells and induced total tumor regression. Consequently, elevated levels of TGF- in the tumor microenvironment enable tumor cells to evade ADCC and resist the antitumor activity of cetuximabin vivo. Our results display that TGF- is definitely a key molecular determinant of thede novoand acquired resistance of cancers to EGFR-targeted mAbs, and provide a rationale for combinatorial focusing on of TGF- to improve anti-EGFRspecific antibody therapy of EGFR-expressing cancers. == Intro == Concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC) is limited by its toxicity and the development of recurrent disease MCH-1 antagonist 1 in MCH-1 antagonist 1 30% to 40% of individuals (1,2). Efforts to improve the treatment of HNSCC have targeted the EGF receptor (EGFR), a receptor tyrosine kinase that is overexpressed and aberrantly triggered in almost all such neoplasms (35). Activation of EGFR signaling promotes tumor cell proliferation and survival, and facilitates tumor angiogenesis (6,7). Strategies to target EGFR have focused on either EGFR tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) that specifically bind the extracellular website of the receptor, such as the humanmouse chimeric IgG1 mAb, cetuximab (8,9). The direct effect of EGFR-targeted mAbs on tumor cells entails specific blockade of EGFR signaling via interference with binding of EGFR ligands to the extracellular website of the receptor (1012). In addition, the interaction of the Fc region of an antibody to Fc receptors on immune effector cells also induces antibody-dependent cellular cytotoxicity (ADCC;refs. 1216). Treatment of individuals with locoregionally advanced HNSCC with a combination of cetuximab and radiation improved overall survival compared with radiation alone (17). Having a median follow-up of 54.0 months, the median duration of overall survival was 49.0 months among patients treated with combined therapy and 29.3 weeks among those treated with radiotherapy alone. However, the survival benefit from cetuximab was not uniformly observed across all individuals. The beneficial effect of cetuximab seemed to be preferentially obvious inside a subset of individuals with the typical characteristics of human being papillomavirus (HPV)-positive head and neck tumor (those with Rabbit Polyclonal to SGCA oropharyngeal cancer who have been males and less than 65 years). After cetuximab and radiation therapy, individuals with HPV-positive tumors showed a 60% 2-yr progression-free survival (PFS) compared with only 23% PFS for individuals with HPV-negative tumors. Recognition of the molecular MCH-1 antagonist 1 determinants of resistance to EGFR-targeted mAbs is vital for improving their clinical benefit against HNSCC. In this study, we find that individuals with HPV-negative HNSCC show an irregular elevation of serum levels of TGF-, a multifunctional cytokine that regulates cell growth and differentiation (18,19). We display that TGF- exerts an extrinsic inhibition of the cytotoxic function of immune effectors while simultaneously providing an intrinsic EGFR-independent survival transmission that protects tumor cells from immune cellmediated ADCC. Even though autonomous manifestation of TGF- enables tumor cells to evade ADCC and resist the antitumor activity of cetuximabin vivo, combinatorial treatment with cetuximab and a TGF-blocking antibody prevents the emergence of such resistant tumor cells and enhances the regression of HNSCC tumor xenografts. These results display that tumor cell manifestation of TGF- is definitely a key determinant of resistance to EGFR-targeted antibodies, and provide a rationale for combinatorial focusing on of TGF- to improve the response of HNSCC and additional EGFR-expressing cancers to cetuximab-based therapy. == Materials and Methods == == Measurement.